Embecta Corp Stock Price, News & Analysis

Embecta Corp. (Nasdaq: EMBC), a leading diabetes care company, announced an upcoming conference call to discuss its fiscal second quarter 2023 results on May 12, 2023, at 8:00 a.m. ET. The call will cover financial results, operational updates, and include a Q&A session. Interested parties can access the live webcast through the company's investor relations website or via teleconference. A replay of the call will be available later that day and archived for one year.

With a legacy of nearly 100 years in insulin delivery and a dedicated workforce of approximately 2,000 employees, Embecta aims to empower individuals with diabetes through innovative solutions.

Embecta Corp. (Nasdaq: EMBC) is hosting a symposium at the ATTD 2023 conference on February 24, 2023, emphasizing the crucial role of people with diabetes in their care. Titled “Diabetes Era of Possibilities: Infusing PwD Choice into Practice!”, the session aims to enhance treatment personalization and discuss insulin injection techniques and diabetes technologies for improved outcomes. The symposium will be chaired by Prof. Dr. Lutz Heinemann and feature key speakers from the diabetes healthcare community. The event underscores the importance of collaboration in care plans to improve the quality of life for diabetes patients.

Embecta Corp. (Nasdaq: EMBC) reported its Q1 fiscal year 2023 results, with revenues of $275.7 million, down 4.7% year-over-year. Adjusted net income was $55.4 million, or $0.96 per diluted share. While U.S. revenues fell 1.1%, international revenues decreased 8.7%, though they rose 2.6% in constant currency. The company raised its fiscal year 2023 revenue guidance to $1,084 - $1,107 million, expecting a 4.0% - 2.0% decline reported and -1.5% - 0.5% in constant currency. A quarterly dividend of $0.15 per share was announced. The CEO expressed confidence in achieving strategic priorities and sustainable success.

The Board of Directors of Embecta Corp. (NASDAQ: EMBC) has declared a quarterly cash dividend of $0.15 per share. This dividend, which reflects the company’s commitment to returning value to its shareholders, will be payable on March 13, 2023, to stockholders of record as of February 27, 2023. Embecta is a leading pure-play diabetes care company, leveraging nearly a century of experience in insulin delivery to enhance the lives of people with diabetes. The company's passion is evident through its workforce of more than 2,000 employees worldwide, focusing on innovative solutions and partnerships.

Embecta Corp. (Nasdaq: EMBC), a leading diabetes care company, announced its participation in several upcoming investor conferences. Management will hold virtual meetings on February 15, 2023, for the 2023 BTIG Medical Technology Conference. A presentation is scheduled for March 6, 2023, at 2:00 p.m. ET during the 2023 JP Morgan Global High Yield and Leveraged Finance Conference in Miami, FL. Additionally, a virtual session will occur on March 14, 2023, at 8:00 a.m. ET for the 2023 Oppenheimer 33rd Annual Healthcare Conference. Audio webcasts of these events will be available on Embecta’s investor relations website.

Campbell Soup Company (NYSE:CPB) announced the appointment of Carrie L. Anderson as Executive Vice President and Chief Financial Officer, effective February 6. Anderson will oversee the finance function including controllership, corporate financial planning, and analysis, among other areas. She succeeds Mick Beekhuizen, who transitioned to President of the Meals & Beverages division. Anderson joins from Integra LifeSciences where she served as CFO since 2019. With a background in diverse industries and a strong financial acumen, her leadership is expected to enhance Campbell's growth and performance.

Embecta Corp. (Nasdaq: EMBC) recently celebrated the grand opening of its new global headquarters in Parsippany, New Jersey, a significant step for the diabetes care company following its spinoff from Becton, Dickinson and Company in April 2022. The 55,600-square-foot office will house the leadership team, global support functions, and North American commercial operations, supporting approximately 2,000 employees worldwide. CEO Devdatt Kurdikar highlighted the strategic advantages of the location, including access to a skilled workforce and transportation. New Jersey Governor Phil Murphy praised Embecta's commitment to expanding the state's public health infrastructure.

Embecta Corp. (Nasdaq: EMBC), a leading diabetes care company, announced that it will host a conference call on February 14, 2023, at 8:00 a.m. ET to discuss its fiscal Q1 2023 financial results and provide operational updates. Investors can join via a live webcast or teleconference. The call will include a question and answer session, and a replay will be available later that day on the company's investor relations website. As a major player in insulin delivery, Embecta aims to support people with diabetes through innovative solutions, leveraging its nearly century-long legacy.

Embecta Corp. (Nasdaq: EMBC) reported its financial results for the fiscal year ended September 30, 2022. Revenues decreased to $1,129.5 million, down 3.1% year-over-year. The fourth quarter saw revenues of $274.6 million, an 8.7% decline. U.S. and international revenues fell 1.5% and 4.8%, respectively. Gross profit was $774.9 million with a margin of 68.6%. Net income was $223.6 million, a sharp drop from $414.8 million the prior year, influenced by a $58.9 million impairment charge. The company announced a dividend of $0.15 per share and provided preliminary fiscal 2023 guidance of revenues between $1,050 to $1,073 million.